Qiagen and Max Planck Institute for Infection Biology (MPIIB) have partnered to develop a molecular diagnostic test to evaluate the risk of an individual with latent tuberculosis (TB) developing active TB during their lifetime.

The new molecular reflex assay, which is based on the QIAsymphony modular automation platform, will be designed to allow early treatment the latent TB reactivates.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The aim of the collaboration is to format the suitable biomarkers identified by the institute into a molecular assay that can detect susceptibility or resistance to active TB in individuals with latent TB.

Under the partnership deal, Qiagen will be responsible for assay design and manufacturing, while the MPIIB will offer access to its marker sets and will develop new biosignatures.

Qiagen vice-president James Rothel said that the assays are highly complementary to its QuantiFERON technology, and hopes that the combination of ‘pre-molecular’ and DNA/RNA-based molecular testing technologies will help in screening and identifying infected individuals before they develop active TB.

”The collaboration with the MPIIB underpins Qiagen’s strategy to further expand its portfolio with new innovative assay technologies for profiling diseases to make improvements in life possible," Rothel said.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company’s pre-molecular technology identifies individuals at risk for life-threatening diseases by examining whole blood samples for the presence of systemically amplified molecular components, which provide information from the immune system’s memory.

MPIIB, Berlin Department of Immunology director Stefan Kaufmann said through the partnership they will gain access to important technologies and concomitantly strengthen the further development of their vaccine programme.

"Results from this research may accelerate clinical trials of TB vaccines. Identification of biomarkers that can predict risk of active TB disease in individuals with latent TB will also be able to predict protective efficacy of a vaccine candidate early in clinical trial," Kaufmann said.